Stocktoria
Xencor Inc XNCR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-12-03
Xencor Inc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -141.4% | -161.5% | -75.8% | -50.1% | 15.9% |
| Net margin | -73.2% | -210.5% | -76.2% | -33.5% | 30.0% |
| FCF margin | -110.1% | -188.5% | -55.2% | -8.5% | -11.0% |
| Return on assets | -10.5% | -24.4% | -13.8% | -6.5% | 9.9% |
| Return on equity | -14.5% | -34.3% | -20.1% | -7.6% | 11.3% |
| Debt / equity | 0.12× | 0.17× | 0.24× | 0.00× | — |
| Current ratio | 6.25 | 6.61 | 8.60 | 10.58 | 6.00 |
| Revenue growth | 13.7% | -36.7% | 6.1% | -40.2% | 124.2% |
Source: SEC EDGAR filings · CIK 0001326732 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.